James J. Perkins

Nonpeptide α_vβ₃ Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent α_vβ₃ Antagonist for the Prevention and Treatment of Osteoporosis

John H. Hutchinson, Wasyl Halczenko, Karen M. Brashear et al. · Journal of Medicinal Chemistry · 2003 · 96 citations · Full text

Pharmacotherapy, Osteoporosis, Selective Antagonist +17

Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors

Timothy E. Johnson, M. Katharine Holloway, Robert L. Vogel et al. · The Journal of Steroid Biochemistry and Molecular Biology · 1997 · 89 citations

Ligand Activation, Biochemistry, Structural Requirements +12

Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist

Mark E. Duggan, Le T. Duong, John Fisher et al. · Journal of Medicinal Chemistry · 2000 · 88 citations · Full text

Discovery of the Selective Androgen Receptor Modulator MK-0773 Using a Rational Development Strategy Based on Differential Transcriptional Requirements for Androgenic Anabolism Versus Reproductive Physiology

Azriel Schmidt, Donald B. Kimmel, Chang Bai et al. · Journal of Biological Chemistry · 2010 · 67 citations · Full text

Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist

Mark E. Duggan, Adel M. Naylor-Olsen, James J. Perkins et al. · Journal of Medicinal Chemistry · 1995 · 65 citations · Full text

Chimpanzee Platelets, Thrombosis, Medicinal Chemistry +15